A 70-year-old woman with shingles: Review of herpes zoster

JAMA

Volumn 302, Issue 1, 2009, Pages 73-80

  Whitley, Richard J ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; CEFACLOR; CIPROFLOXACIN; CODEINE; FLUTICASONE; GABAPENTIN; HYDROCHLOROTHIAZIDE PLUS TRIAMTERENE; IODINE; OMEPRAZOLE; PARACETAMOL; PENICILLIN DERIVATIVE; SALBUTAMOL; SALMETEROL; SERTRALINE; SULFONAMIDE; VALACICLOVIR; VERAPAMIL; ANALGESIC AGENT; ANTIVIRUS AGENT; CHICKENPOX VACCINE; GLUCOCORTICOID; VARICELLA ZOSTER VACCINE;

AGED; ANAMNESIS; BEDTIME DOSAGE; CASE REPORT; CLINICAL FEATURE; FEMALE; HERPES ZOSTER; HERPES ZOSTER OTICUS; HUMAN; LABORATORY TEST; NEUROLOGIC EXAMINATION; OTALGIA; PAIN; PHYSICAL EXAMINATION; PRIORITY JOURNAL; REVIEW; CLINICAL OBSERVATION; CLINICAL STUDY; DIAGNOSIS; ECONOMICS; IMMUNOCOMPETENCE; IMMUNOLOGY; POSTHERPETIC NEURALGIA;

AGED; ANALGESICS; ANTIVIRAL AGENTS; CHICKENPOX VACCINE; FEMALE; GLUCOCORTICOIDS; HERPES ZOSTER; HERPES ZOSTER OTICUS; HERPES ZOSTER VACCINE; HUMANS; IMMUNOCOMPETENCE; NEURALGIA, POSTHERPETIC;

EID: 67649979981     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2009.822     Document Type: Review

References (82)

1. Gnann JW Jr, Whitley RJ. Herpes zoster. N Engl J Med. 2002;347(5):340-346.
2. Straus SE, Reinhold W, Smith HA, et al. Endonuclease analysis of viral DNA from varicella and subsequent zoster infections in the same patient. N Engl J Med. 1984; 311(21):1362-1364.
3. Arvin AM. Humoral and cellular immunity to varicella-zoster virus: an overview. J Infect Dis. 2008;197(suppl 2):S58-S60.
4. Donahue JG, Choo PW, Manson JE, Platt R. The incidence of herpes zoster. Arch Intern Med. 1995;155(15):1605-1609.
5. Ragozzino MW, Melton LJ III, Kurland LT, Chu CP, Perry HO. Populations-based study of herpes zoster and its sequelae. Medicine (Baltimore). 1982; 61(5):310-316.
6. Harpaz JTR. Considerations for shingles vaccine recommendations in the US. http://www.cdc.gov/vaccines/recs/acip/downloads/min-jun06.pdf. Accessed January 25, 2007.
7. Gershon A, Perkin R. Herpes zoster. N Engl J Med. 2000;343(3):222.
8. Oxman MN, Levin M, Johnson G, et al; Shingles Prevention Study Group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271-2284.
9. Choo PW, Donahue JG, Manson JE, Platt R. The epidemiology of varicella and its complications. J Infect Dis. 1995;172(3):706-712.
10. Brisson M, Edmunds W, Law B, et al. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect. 2001;127(2): 305-314.
11. Buchbinder SP, Katz M, Hessol N, et al. Herpes zoster and human immunodeficiency virus infection. J Infect Dis. 1992;166(5):1153-1156.
12. Hope-Simpson RE. The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med. 1965;58:9-20.
13. Weller TH. Varicella and herpes zoster: changing concepts of the natural history, control, and importance of a not-so-benign virus. N Engl J Med. 1983; 309(23):1434-1440.
14. Whitley R. Varicella-zoster virus. In: Mandell G, Bennett J, Dolin R, eds. Principles and Practice of Infectious Disease. 6th ed. Philadelphia, PA: Churchill Livingston; 2005:1780-1786.
15. Gilden DH, Kleinschmidt-DeMasters BK, LaGuardia JJ, Mahalingam R, Cohrs RJ. Neurologic complications of the reactivation of varicella-zoster virus. N Engl J Med. 2000;342(9):635-645.
16. Whitley R. Varicella-zoster virus infections. In: Fauci A, Kasper D, Braunwald E, eds, et al. Harrison's Principles of Internal Medicine. 17th ed. New York, NY: McGraw-Hill; 2004.
17. Arani RB, Soong S-J, Weiss HL, et al. Phase specific analysis of herpes zoster associated pain data: a new statistical approach. Stat Med. 2001;20(16):2429-2439.
18. Desmond RA, Weiss HL, Arani RB, et al. Clinical applications for change-point analysis of herpes zoster pain. J Pain Symptom Manage. 2002;23(6): 510-516.
19. Jung BF, Johnson RW, Griffin DR, Dworkin RH. Risk factors for postherpetic neuralgia in patients with herpes zoster. Neurology. 2004;62(9):1545-1551.
20. Choo PW, Galil K, Donahue J, Walker A, Spiegelman D, Platt R. Risk factors for postherpetic neuralgia. Arch Intern Med. 1997;157(11):1217- 1224.
21. Bowsher D. The effects of pre-emptive treatment of postherpetic neuralgia with amitriptyline: a randomized, double-blind, placebo-controlled trial. J Pain Symptom Manage. 1997;13(6):327-331.
22. McKendrick MW, McGill JI, Wood MJ. Lack of effect of acyclovir on postherpetic neuralgia. BMJ. 1989;298(6671):431.
23. Brown GR. Herpes zoster: correlation of age, sex, distribution, neuralgia, and associated disorders. South Med J. 1976;69(5):576-578.
24. Dworkin RH, Backonja M, Rowbotham MC, et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol. 2003; 60(11):1524-1534.
25. Dworkin RH, Gnann JW Jr, Oaklander AL, Raja SN, Schmader KE, Whitley RJ. Diagnosis and assessment of pain associated with herpes zoster and postherpetic neuralgia. J Pain. 2008;9(1)(suppl 1):S37-S44.
26. Dworkin RH, Johnson RW, Breuer J, et al. Recommendations for the management of herpes zoster. Clin Infect Dis. 2007;44(suppl 1):S1-S26.
27. Dworkin RH, Portenoy RK. Pain and its persistence in herpes zoster. Pain. 1996; 67(2-3):241-251.
28. Haanpää M, Laippala P, Nurmikko T. Allodynia and pinprick hypesthesia in acute herpes zoster, and the development of postherpetic neuralgia. J Pain Symptom Manage. 2000;20(1):50-58.
29. Rogers RS III, Tindall JP. Geriatric herpes zoster. J Am Geriatr Soc. 1971; 19(6):495-504.
30. Scott FT, Johnson R, Leedham-Green M, Davies E, Edmunds W, Breuer J. The burden of herpes zoster: a prospective population based study. Vaccine. 2006; 24(9):1308-1314.
31. Scott FT, Leedham-Green M, Barrett-Muir W, et al. A study of shingles and the development of postherpetic neuralgia in East London. J Med Virol. 2003; 70(suppl 1):S24-S30.
32. Liesegang TJ. Diagnosis and therapy of herpes zoster ophthalmicus. Ophthalmology. 1991;98(8):1216-1229.
33. Ormerod L, Larkin J, Margo C, et al. Rapidly progressive herpetic retinal necrosis: a blinding disease characteristic of advanced AIDS. Clin Infect Dis. 1998; 26(1):34-45.
34. Dahl H, Marcoccia J, Linde A. Antigen detection: the method of choice in comparison with virus isolation and serology for laboratory diagnosis of herpes zoster in human immunodeficiency virus-infected patients. J Clin Microbiol. 1997; 35(2):347-349.
35. Vázquez M, LaRussa PS, Gershon AA, Steinberg SP, Freudigman K, Shapiro ED. The effectiveness of the varicella vaccine in clinical practice. N Engl J Med. 2001;344(13):955-960.
36. Wood MJ, Kay R, Dworkin RH, Soong S-J, Whitley RJ. Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a meta-analysis of placebo-controlled trials. Clin Infect Dis. 1996;22(2):341-347.
37. Beutner KR, Friedman DJ, Forszpaniak C, Andersen PL, Wood MJ. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother. 1995;39(7):1546- 1553.
38. Tyring S, Barbarash RA, Nahlik JE, et al; Collaborative Famciclovir Herpes Zoster Study Group. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1995;123(2):89-96.
39. Degreef H; Famciclovir Herpes Zoster Clinical Study Group. Famciclovir, a new oral antiherpes drug: results of the first controlled clinical study demonstrating its efficacy and safety in the treatment of uncomplicated herpes zoster in immunocompetent patients. Int J Antimicrob Agents. 1994;4(4):241-246.
40. Tyring SK, Beutner KR, Tucker BA, Anderson WC, Crooks RJ. Antiviral therapy for herpes zoster: randomized, controlled clinical trial of valacyclovir and famciclovir therapy in immunocompetent patients 50 years and older. Arch Fam Med. 2000;9(9):863-869.
41. Gnann JW Jr, Crumpacker CS, Lalezari JP, et al; Collaborative Antiviral Study Group/AIDS Clinical Trials Group; Herpes Zoster Study Group. Sorivudine versus acyclovir for treatment of dermatomal herpes zoster in human immunodeficiency virus-infected patients: results from a randomized, controlled clinical trial. Antimicrob Agents Chemother. 1998;42(5):1139-1145.
42. Huff JC, Bean B, Balfour HH Jr, et al. Therapy of herpes zoster with oral acyclovir. Am J Med. 1988;85(2A):84-89.
43. McKendrick MW, McGill JI, White JE, Wood MJ. Oral acyclovir in acute herpes zoster. Br Med J (Clin Res Ed). 1986;293(6561):1529-1532.
44. Morton P, Thomson AN. Oral acyclovir in the treatment of herpes zoster in general practice. N Z Med J. 1989;102(863):93-95.
45. Li Q, Chen N, Yang J, et al. Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database Syst Rev. 2009;(2):CD006866.
46. Worthington M. Costs to Treat Zoster. Birmingham: Children's Hospital of Alabama Pharmacy; 2009.
47. Redbook: Pharmacy's Fundamental Reference. Montvale, NJ: Thomson; 2008.
48. Wood MJ, Johnson RW, McKendrick MW, Taylor J, Mandal BK, Crooks J. A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. N Engl J Med. 1994;330(13): 896-900.
49. Whitley RJ, Weiss H, Gnann J Jr, et al; National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Acyclovir with and without prednisone for the treatment of herpes zoster: a randomized, placebo-controlled trial. Ann Intern Med. 1996;125(5):376-383.
50. Kost RG, Straus SE. Postherpetic neuralgia-pathogenesis, treatment, and prevention. N Engl J Med. 1996;335(1):32-42.
51. Volmink J, Lancaster T, Gray S, Silagy C. Treatments for postherpetic neuralgia: a systematic review of randomized controlled trials. Fam Pract. 1996;13 (1):84-91.
52. Watson CP, Babul N. Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. Neurology. 1998;50(6):1837-1841.
53. Kishore-Kumar R, Max MB, Schafer SC, et al. Desipramine relieves postherpetic neuralgia. Clin Pharmacol Ther. 1990;47(3):305-312.
54. Max MB, Schafer SC, Culnane M, Smoller B, Dubner R, Gracely RH. Amitriptyline but not lorazepam, relieves postherpetic neuralgia. Neurology. 1988; 38(9):1427-1432.
55. Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA. 1998;280(21):1837-1842.
56. Drugs.com. Gabapentin. http://www.drugs.com/pdr/gabapentin.html. Accessed March 26, 2009. 57. Lexi-Comp Clinical On-Line Databases. Gabapentin. http://www.crlonline.com.ezproxy.samford.edu/crlsql/servlet/crlonline/. Accessed May 26, 2009.
57. Dworkin RH, Corbin AE, Young JP Jr, et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology. 2003; 60(8):1274-1283.
58. Dworkin RH, Barbano RL, Tyring SK, et al. A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster. Pain. 2009; 142(3):209-217.
59. Bernstein JE, Korman NJ, Bickers DR, Dahl MV, Millikan LE. Topical capsaicin treatment of chronic postherpetic neuralgia. J Am Acad Dermatol. 1989;21 (2 pt 1):265-270.
60. Rowbotham MC, Davies PS, Verkempinck C, Galer BS. Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia. Pain. 1996;65(1):39-44.
61. Galer BS, Rowbotham MC, Perander J, Friedman E. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. Pain. 1999;80(3):533-538.
62. Kotani N, Kushikata T, Hashimoto H, et al. Intrathecal methylprednisolone for intractable postherpetic neuralgia. N Engl J Med. 2000;343(21):1514-1519.
63. Guris D, Jumaan AO, Mascola L, et al. Changing varicella epidemiology in active surveillance sites-United States, 1995-2005. J Infect Dis. 2008;197 (suppl 2):S71-S75.
64. Seward JF, Marin M, Vazquez M. Varicella vaccine effectiveness in the US vaccination program: a review. J Infect Dis. 2008;197(suppl 2):S82-S89.
65. Reynolds MA, Watson BM, Plott-Adams KK, et al. Epidemiology of varicella hospitalizations in the United States, 1995-2005. J Infect Dis. 2008;197(suppl 2): S120-S126.
66. Zhou F, Harpaz R, Jumaan AO, Winston CA, Shefer A. Impact of varicella vaccination on health care utilization. JAMA. 2005;294(7):797-802.
67. Centers for Disease Control and Prevention. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). May 15, 2008. http://www.cdc.gov/mmwr/preview/mmwrhtml/rr57e0515a1.htm?s-cid= rr57e0515-e. Accessed June 2, 2009.
68. Chaves SS, Gargiullo P, Zhang JX, et al. Loss of vaccine-induced immunity to varicella over time. N Engl J Med. 2007;356(11):1121-1129.
69. Michalik DE, Steinberg SP, Larussa PS, et al. Primary vaccine failure after 1 dose of varicella vaccine in healthy children. J Infect Dis. 2008;197(7):944-949.
70. Gershon AA, Arvin AM, Shapiro E. Varicella vaccine. N Engl J Med. 2007; 356(25):2648-2649, author reply 2648-2649.
71. Reynolds MA, Chaves SS, Harpaz R, Lopez AS, Seward JF. The impact of the varicella vaccination program on herpes zoster epidemiology in the United States: a review. J Infect Dis. 2008;197(suppl 2):S224-S227.
72. Whitley RJ. Changing dynamics of varicella-zoster virus infections in the 21st century: the impact of vaccination. J Infect Dis. 2005;191(12):1999-2001.
73. Levin MJ, Barber D, Goldblatt E, et al. Use of a live attenuated varicella vaccine to boost varicella-specific immune responses in seropositive people 55 years of age and older: duration of booster effect. J Infect Dis. 1998;178(suppl 1): S109-S112.
74. Zostavax [package insert]. Whitehouse Station, NJ: Merck & Co; 2006. http://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ ucm132831.pdf. Accessed January 25, 2007.
75. ProQuad [package insert]. Whitehouse Station, NJ: Merck & Co; 2005. http://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ ucm123793. Accessed January 25, 2007.
76. Varivax [package insert]. Whitehouse Station, NJ: Merck & Co; 2005. http://www.fda.govhttp://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/ approvedproducts/ucm142812. Accessed January 25, 2007.
77. Levin MJ, Murray M, Zerbe GO, White CJ, Hayward AR. Immune response of elderly persons 4 years after receiving a live attenuated varicella vaccine. J Infect Dis. 1994;170(3):522-526.
78. Oxman MN. Immunization to reduce the frequency and severity of herpes zoster and its complications. Neurology. 1995;45(12)(suppl 8):S41-S46.
79. Trannoy E, Berger R, Hollander G, et al. Vaccination of immunocompetent elderly subjects with a live attenuated Oka strain of varicella zoster virus: a randomized, controlled, dose-response trial. Vaccine. 2000;18(16):1700-1706.
80. Wiffen PJ, McQuay HJ, Edwards JE, Moore RA. Gabapentin for acute and chronic pain. Cochrane Database Syst Rev. 2005;(3):CD005452.
81. Hardy I, Gershon AA, Steinberg SP, LaRussa P; Varicella Vaccine Collaborative Study Group. The incidence of zoster after immunization with live attenuated varicella vaccine: a study in children with leukemia. N Engl J Med. 1991;325 (22):1545-1550.
82. Gershon AA, LaRussa P, Hardy I, Steinberg S, Silverstein S. Varicella vaccine: the American experience. J Infect Dis. 1992;166(suppl 1):S63-S68.